8-K - Upstream Bio, Inc. (0002022626) (Filer)

8-K - Upstream Bio, Inc. (0002022626) (Filer)

SCHEDULE 13G/A - Upstream Bio, Inc. (0002022626) (Subject)

SCHEDULE 13G/A - Upstream Bio, Inc. (0002022626) (Subject)

S-3ASR - Upstream Bio, Inc. (0002022626) (Filer)

10-Q - Upstream Bio, Inc. (0002022626) (Filer)

8-K - Upstream Bio, Inc. (0002022626) (Filer)

SCHEDULE 13G - Upstream Bio, Inc. (0002022626) (Subject)

8-K - Upstream Bio, Inc. (0002022626) (Filer)

SCHEDULE 13G/A - Upstream Bio, Inc. (0002022626) (Subject)

– Verekitug provided statistically significant and clinically meaningful reductions in annualized asthma exacerbation rate (AAER) with 100 mg q12 and 400 mg q24 week dosing – – Verekitug also delivered clinically meaningful improvements in lung function (FEV1) and exhaled nitric oxide (FeNO) with both dose regimens – – Verekitug was generally well tolerated, with a safety profile consistent with prior studies – – Over 90% of eligible patients have rolled over to the Phase 2 VALOUR long-term extension study – – Upstream Bio to advance verekitug into Phase 3 trials in severe asthma and CRSwNP following planned regulatory interactions – – Management will host a live webcast today at 8:00

WALTHAM, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced it will report top-line results from the Phase 2 VALIANT trial of verekitug, the only known antagonist currently in clinical development that targets and inhibits the thymic stromal lymphopoietin (TSLP) receptor, on Wednesday, February 11, 2026 at 8:00 a.m. ET. The VALIANT trial (NCT06196879) is a Phase 2 global, randomized, double-blind, placebo-controlled, dose-ranging, parallel group clinical trial that evaluated the safety and efficacy of verekitug for up to 60

WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will be presenting at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 2:15 p.m. PT. A live webcast of the presentation will be available under the Events tab on the Investors section of Upstream Bio's website on the day of the event. A replay will be available on the Company's website following the presentation. About Upstream BioUpstream Bio is a clinical-stage bi

WALTHAM, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will be participating in the following upcoming investor conferences in December: Piper Sandler 37th Annual Healthcare Conference, New York, NYTuesday, December 2, 2025, Fireside Chat – 4:30 p.m. ET8th Annual Evercore Healthcare Conference, Miami, FLThursday, December 4, 2025, Fireside Chat – 10:25 a.m. ET Live webcasts of the presentations will be available under the Events tab on the Investors se

– Positive top-line results from VIBRANT Phase 2 trial of verekitug in CRSwNP reported in September showed statistically significant and clinically meaningful effects on primary and key secondary endpoints when administered once every 12 weeks – – On-track to report top-line results from VALIANT Phase 2 trial in severe asthma in the first quarter of 2026 – – Enrollment ongoing in VENTURE Phase 2 trial in COPD; first patient dosed in July – WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today reported financial results for th

WALTHAM, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will be participating in the following upcoming investor conferences in November: 2025 Truist Securities BioPharma Symposium, New York, NYThursday, November 6, 2025, Panel - 8:10 a.m. ETStifel 2025 Healthcare Conference, New York, NYTuesday, November 11, 2025, Presentation - 9:20 a.m. ET TD Cowen Immunology and Inflammation Summit, VirtualWednesday, November 12, 2025, Fireside Chat - 10:30 a.m. ET

– Data show verekitug prevents TSLP binding to the TSLP receptor by occupying ligand binding sites – – Additionally, findings show that verekitug outcompetes TSLP in the presence of preformed heterodimeric receptor complexes – – Data support the potential of verekitug's unique mechanism of action to achieve a differentiated therapeutic effect across a broad range of TSLP-driven severe respiratory diseases – WALTHAM, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today presented structural and mechanistic data showing verekitug

WALTHAM, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will participate in a fireside chat at the Stifel 2025 Virtual Immunology and Inflammation Forum on September 15, 2025 at 10:30 a.m. ET. A live webcast of the fireside chat will be available under the Events tab on the Investors section of the Company's website. A replay will be posted on the Company's website following the presentation. About Upstream BioUpstream Bio is a clinical-stage biotechno

– In this 24-week study, VIBRANT met its primary endpoint, with verekitug dosed every 12 weeks leading to a statistically significant and clinically meaningful reduction from baseline in placebo-adjusted endoscopic nasal polyp score (NPS) of -1.8 (p<0.0001) – – Significant and clinically meaningful improvements were observed in key secondary endpoints, including -0.8 (p=0.0003) reduction in nasal congestion score and 76% (p=0.03) reduction in need for surgery or systemic corticosteroids – – No serious adverse events (SAEs) observed; generally well tolerated safety profile consistent with previous studies – – Observed clinical effect on endoscopic NPS in this Phase 2 trial suggests verekit

WALTHAM, Mass., Sept. 01, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced it will report top-line data from the Phase 2 VIBRANT trial of verekitug, the only known clinical-stage monoclonal antibody targeting the receptor for thymic stromal lymphopoietin (TSLP), on Tuesday, September 2, 2025. The VIBRANT trial (NCT06164704) was a Phase 2 global, randomized, placebo-controlled, parallel group clinical trial designed to assess the efficacy and safety of verekitug in adults with CRSwNP. Participants received either 100 mg of verekitug or pl